Vietnam‑Cuba biotech collaboration

In late July 2026, Vietnamese biopharma firm Genfarma received a Good Manufacturing Practice (GMP) certificate from the country's drug regulator, confirming that its high‑tech plant meets WHO‑GMP and EU‑GMP standards. The certification was presented alongside a joint ceremony with Cuban biotech partners, marking the completion of a technology transfer that equips Genfarma to produce the anti‑cancer monoclonal antibody nimotuzumab for head‑and‑neck cancer. The event also highlighted Cuba’s export of advanced diagnostic platforms, including UMELISA hepatitis B and C tests, underscoring a broader strategy to supply Vietnam with both therapeutic and diagnostic biomedical tools.

The collaboration reflects a deepening partnership: Genfarma’s new GMP‑certified facility, built with automated, data‑driven systems, will serve as both a production hub and a research centre, while Cuban expertise provides the know‑how for antibody‑based therapies and high‑sensitivity diagnostic assays. Together, the two countries aim to reduce Vietnam’s reliance on imported biologics and strengthen regional biotech capacity.